AR056613A1 - Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen - Google Patents

Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen

Info

Publication number
AR056613A1
AR056613A1 ARP030104253A ARP030104253A AR056613A1 AR 056613 A1 AR056613 A1 AR 056613A1 AR P030104253 A ARP030104253 A AR P030104253A AR P030104253 A ARP030104253 A AR P030104253A AR 056613 A1 AR056613 A1 AR 056613A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
prevention
treatment
lapachona
Prior art date
Application number
ARP030104253A
Other languages
English (en)
Inventor
Jiang Zhiwei
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Publication of AR056613A1 publication Critical patent/AR056613A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/08—Naphthothiopyrans; Hydrogenated naphthothiopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/06—Six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Análogos y derivados de lapachona como así también métodos de uso y de preparacion de los mismos. Estos compuestos pueden ser usados en composiciones farmacéuticas para el tratamiento o la prevencion de trastornos proliferativos celulares. Estos compuestos también pueden ser usados en el tratamiento o la prevencion de psoriasis o cáncer o condiciones pre-cancerosas. Reivindicacion 1: Un compuesto caracterizado por la formula (1) o sales farmacéuticamente aceptables del mismo, o una mezcla regioisomérica del mismo, donde R1-R6 son cada uno, independientemente, seleccionados del grupo formado por H, OH, alquilo C1-6 substituido y no substituido, alquenilo C1-6 substituido y n substituido, alcoxi C1-6 substituido y no substituido, alcoxicarbonilo C1-6 substituido y no substituido, acilo C1-6 substituido y no substituido, -(CH2)n-amino, -(CH2)n-arilo, -(CH2)-heterociclilo, y -(CH2)n-fenilo; o uno de R1 o R2 y uno de R3 o R4; o uno de R3 o R4 y uno de R5 o R6 forman un anillo fusionado, donde el anillo tiene de 4-8 miembros anulares; R7-R10 son cada uno, independientemente, H, hidroxilo, halogeno, alquilo substituido o no substituido, alcoxi substituido o n substituido, nitro, ciano o amida; y n es un entero de 0 a 10.
ARP030104253A 2002-11-18 2003-11-18 Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen AR056613A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42728302P 2002-11-18 2002-11-18

Publications (1)

Publication Number Publication Date
AR056613A1 true AR056613A1 (es) 2007-10-17

Family

ID=34375156

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104253A AR056613A1 (es) 2002-11-18 2003-11-18 Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen

Country Status (12)

Country Link
US (1) US20040266857A1 (es)
EP (1) EP1567515A4 (es)
JP (1) JP2006508147A (es)
CN (1) CN1729183A (es)
AR (1) AR056613A1 (es)
AU (1) AU2003295738A1 (es)
BR (1) BR0316296A (es)
CA (1) CA2506340A1 (es)
EA (1) EA200500849A1 (es)
MX (1) MXPA05005314A (es)
TW (1) TW200510367A (es)
WO (1) WO2004045557A2 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575580A4 (en) 2002-12-02 2009-06-10 Arqule Inc METHODS OF TREATING CANCERS
EP1694322A2 (en) 2003-11-26 2006-08-30 Arqule, Inc. Use of beta-lapachone for protecting against radiation injury
EP1729760A2 (en) * 2004-02-20 2006-12-13 Arqule, Inc. Use of beta-lapachone for the treatment of lung cancer
CA2556789A1 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating hematologic tumors
WO2005082355A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treatment of colon cancer
WO2005082353A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for treating or preventing cancer
US20050187288A1 (en) * 2004-02-20 2005-08-25 Chiang Li Beta-lapachone and methods of treating cancer
WO2005082359A2 (en) * 2004-02-20 2005-09-09 Arqule, Inc. Use of beta-lapachone for the treatment of pancreatic cancer
JP2007523192A (ja) * 2004-02-20 2007-08-16 アークル・インコーポレーテツド 広域スペクトラム抗癌剤としてのβ−ラパコンの使用
WO2006020722A2 (en) 2004-08-11 2006-02-23 Arqule, Inc. Polymer conjugates of beta-lapachone and beta-lapachone analogs for tumor targeting
US8614228B2 (en) 2004-08-11 2013-12-24 Arqule, Inc. Quinone prodrug compositions and methods of use
US20060204981A1 (en) 2005-01-07 2006-09-14 Chiang Li Compositions for modulation of PARP and methods for screening for same
WO2006128120A2 (en) * 2005-05-26 2006-11-30 Arqule, Inc. Novel lapachone compounds and methods of use thereof
CA2653472A1 (en) * 2006-05-26 2007-12-06 Arqule, Inc. Novel lapachone compounds and methods of use thereof
TW200824692A (en) 2006-08-21 2008-06-16 Arqule Inc Novel lapachone compounds and methods of use thereof
EP2137168B1 (en) 2007-03-16 2016-09-14 Lankenau Institute for Medical Research Novel ido inhibitors and methods of use thereof
CN101687835B (zh) 2007-04-30 2015-08-19 艾科尔公司 苯醌化合物的羟基磺酸盐和它们的应用
US8067459B2 (en) 2007-10-16 2011-11-29 Arqule, Inc. Lapachone compounds and methods of use thereof
KR101405823B1 (ko) 2007-12-24 2014-06-12 주식회사 케이티앤지생명과학 녹내장의 치료 및 예방을 위한 약제 조성물
KR20090071829A (ko) * 2007-12-28 2009-07-02 주식회사 머젠스 신장질환의 치료 및 예방을 위한 약제 조성물
KR20090073381A (ko) * 2007-12-31 2009-07-03 주식회사 머젠스 심장질환의 치료 및 예방을 위한 약제 조성물
EP2575740A4 (en) * 2010-06-01 2015-09-30 Belle Aire Fragrances Inc METHOD AND PRODUCT FOR COMBATTING ORAL ODORS
WO2017106624A1 (en) 2015-12-18 2017-06-22 The Board Of Regents Of The University Of Texas System Napthoquinones, pro-drugs, and methods of use thereof
KR101735275B1 (ko) 2016-12-20 2017-05-16 아주대학교산학협력단 베타-라파촌을 포함하는 수면 장애 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2011455B (en) * 1977-12-21 1982-03-03 Ici Ltd Chemical process
US5346917A (en) * 1991-06-10 1994-09-13 Sterling Winthrop Inc. Thioxanthenone antitumor agents
US5763625A (en) * 1995-04-25 1998-06-09 Wisconsin Alumni Research Foundation Synthesis and use of β-lapachone analogs
US6245807B1 (en) * 1995-08-24 2001-06-12 Dana-Farber Cancer Institute Treatment of human prostate disease
US5883270A (en) * 1996-02-20 1999-03-16 Wisconsin Alumni Research Foundation 4-substituted-1, 2-naphthoquinones and their use in the inhibition of neoplastic cell growth
US5824700A (en) * 1996-02-20 1998-10-20 Wisconsin Alumni Research Foundation Ortho-quinone derivatives novel synthesis therefor and their use in the inhibition of neoplastic cell growth
JP2002541200A (ja) * 1999-04-14 2002-12-03 デイナ−ファーバー キャンサー インスティチュート，インコーポレイテッド 癌の処置のための方法および組成物
AU2003254029A1 (en) * 2002-07-17 2004-02-02 Arqule, Inc. Activated checkpoint therapy and methods of use thereof

Also Published As

Publication number Publication date
US20040266857A1 (en) 2004-12-30
EA200500849A1 (ru) 2006-02-24
EP1567515A2 (en) 2005-08-31
CA2506340A1 (en) 2004-06-03
TW200510367A (en) 2005-03-16
BR0316296A (pt) 2005-12-13
CN1729183A (zh) 2006-02-01
WO2004045557A2 (en) 2004-06-03
WO2004045557A3 (en) 2004-08-12
EP1567515A4 (en) 2008-04-23
JP2006508147A (ja) 2006-03-09
MXPA05005314A (es) 2005-10-19
AU2003295738A1 (en) 2004-06-15

Similar Documents

Publication Publication Date Title
AR056613A1 (es) Compuestos derivados de lapachona, su preparacion y metodos de uso de los mismos para el tratamiento o prevencion de trastornos proliferativos celulares y composiciones farmaceuticas que los contienen
AR046200A1 (es) Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas
ECSP034431A (es) N-oxidos como profarmacos antagonistas del receptor nk1 de derivados de 4-fenil-piridina
ECSP034475A (es) Derivados de 4-fenil-piridin como antagonistas del receptor de neuroquinina-1
PE20020721A1 (es) Derivados de quinuclidina como agentes antimuscarinicos m3
AR052902A1 (es) Derivados de piridazina, composicion farmaceutica que los contiene y su uso como agentes terapeuticos para enfermedades mediadas por la estearoil-coa desaturasa
AR029301A1 (es) Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos
AR046309A1 (es) Derivados de dihidrobenzofuranilo alcanamina, metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de trastornos del sistema nervioso central.
AR035892A1 (es) Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos
AR041566A1 (es) Derivados de indol utiles para el tratamiento de enfermedades
AR022303A1 (es) Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
AR074876A1 (es) Derivados de indol-pirimidina para tratar cancer
AR054799A1 (es) Derivados de oxindol
AR056195A1 (es) Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
PE20020735A1 (es) Derivados de quinazolona como antagonistas de receptores adrenergicos alfa-1a/b
UA72917C2 (en) Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
AR064547A1 (es) Derivados de azaspiro como antagonistas del receptor v1a
PE20030761A1 (es) Derivados del 7-amino-benzotiazol
PE20020657A1 (es) Derivados de amida de piperidinas 1,4-disustituidas de formula (i)
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ECSP045073A (es) Nuevos derivados de piperazina
UY26048A1 (es) Derivados de piridopiranoacepinas, su preparacion y su aplicacion terapeutica
AR034174A1 (es) Compuestos de benzoxazinona, procedimiento para su preparacion, composiciones farmaceuticas que lo comprenden, procedimiento para la preparacion de tales composiciones, y el uso de dichos compuestos o composiciones en la fabricacion de medicamentos
AR034585A1 (es) Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos
AR043537A1 (es) Derivados azabiciclicos de piridiloximetilo y bencisoxazol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal